Pfizer's Lessons On Breakthrough Designation: Be Strategic, Work Hard
This article was originally published in SRA
Executive Summary
Companies often view getting US breakthrough therapy status for their products as the key to obtaining significant feedback from Food and Drug Administration, but sponsors hoping to achieve that designation should be engaged with the agency well before that seek it, according to Andrew Emmett, Senior Director for Pfizer Inc.'s FDA Liaison Office.